Home › NDC Lookup › RxCUI directory › RxCUI 583257

Mesalamine 1000 MG Rectal Suppository [Canasa] — RxCUI 583257

RxNorm drug concept · Semantic branded drug
RxCUI 583257 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI583257
Official nameMesalamine 1000 MG Rectal Suppository [Canasa]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asCanasa 1000 MG Rectal Suppository
FDA products mapped1
Package NDCs mapped3
Reported Medicaid activity (SDUD)300 prescriptions · 4 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Mesalamine Rectal: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Mesalamine rectal works by calming the inflammation directly in the lining of your rectum and lower colon — the area affected by your condition. It blocks some of the chemical sign...
  • What exactly is this medication doing for my colitis?
  • Treatment is typically continued for 3 to 6 weeks depending on your symptoms and what your doctor sees during examination. It's important to keep using it for the full course your...
  • How long do I need to use it before it starts working?
📖 Read our full Mesalamine Rectal guide →

🕸️ Concept Web — How Mesalamine 1000 MG Rectal Suppository [Canasa] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Mesalamine 1000 MG Rectal Suppository [Canasa] RxCUI 583257

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Mesalamine 52582
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Canasa 196493
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Mesalamine Rectal Suppository 372786
    • Mesalamine Rectal Product 1165716
    • Mesalamine Rectal Suppository [Canasa] 367530
    • Canasa Rectal Product 1172309
    • Rectal Suppository 316978
    • Rectal Product 1151127
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

  • Mesalamine 1000 MG [Canasa] SBDC · 583256
  • Mesalamine Rectal Suppository [Canasa] SBDF · 367530
  • Canasa Rectal Product SBDG · 1172309
  • Canasa BN · 196493

📦 FDA Products & Package NDCs

1 product · 3 package NDCs
3 package NDCs map to RxCUI 583257 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
58914-0501-33 3 SUPPOSITORY in 1 BOX (58914-501-33) Canasa Allergan, Inc. 2001-01-05
58914-0501-42 42 SUPPOSITORY in 1 BOX (58914-501-42) Canasa Allergan, Inc. 2001-01-05
58914-0501-56 30 SUPPOSITORY in 1 BOX (58914-501-56) Canasa Allergan, Inc. 2001-01-05
Observed labelers: Allergan, Inc. (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$37.0900
Range $37.0900–$37.0900 · middle 50% $37.0900–$37.0900 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.